Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as $93.77 and last traded at $91.47, with a volume of 539263 shares. The stock had previously closed at $86.51.
Wall Street Analysts Forecast Growth
Several research firms recently commented on ABVX. Piper Sandler raised their price target on shares of Abivax from $70.00 to $112.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 29th. BTIG Research raised their price target on shares of Abivax from $112.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Abivax in a research note on Wednesday. JMP Securities increased their target price on shares of Abivax from $95.00 to $114.00 and gave the stock a "market outperform" rating in a report on Thursday, September 25th. Finally, Citigroup reiterated an "outperform" rating on shares of Abivax in a report on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Abivax presently has an average rating of "Moderate Buy" and a consensus price target of $103.29.
Get Our Latest Report on ABVX
Abivax Price Performance
The business's 50-day moving average price is $79.39 and its 200-day moving average price is $34.46.
Abivax (NASDAQ:ABVX - Get Free Report) last issued its quarterly earnings data on Monday, September 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.04. As a group, research analysts forecast that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.
Institutional Trading of Abivax
A number of institutional investors have recently bought and sold shares of ABVX. Bank of America Corp DE boosted its stake in Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after purchasing an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock worth $63,000 after purchasing an additional 2,595 shares in the last quarter. GAMMA Investing LLC boosted its stake in Abivax by 373.6% in the 1st quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock worth $118,000 after purchasing an additional 14,855 shares in the last quarter. XTX Topco Ltd acquired a new stake in Abivax in the 2nd quarter worth approximately $139,000. Finally, Two Sigma Investments LP acquired a new stake in Abivax in the 4th quarter worth approximately $144,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.
About Abivax
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
